Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NBIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 141.65 | 06:41:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 141.65 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 89.04 - 148.3699 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 141.65 | USD |
Neurocrine Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 14.1B | 99.51M | - | 1.89B | 249.7M | 2.51 | 56.45 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Neurocrine Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 137.12 | 143.05 | 134.79 | 141.27 | 627,138 | 4.53 | 3.30% |
| 1 Month | 141.00 | 145.22 | 134.79 | 139.86 | 778,070 | 0.65 | 0.46% |
| 3 Months | 135.12 | 148.3699 | 129.15 | 138.02 | 851,977 | 6.53 | 4.83% |
| 6 Months | 109.89 | 148.3699 | 108.63 | 133.72 | 821,408 | 31.76 | 28.90% |
| 1 Year | 94.27 | 148.3699 | 89.04 | 119.86 | 767,207 | 47.38 | 50.26% |
| 3 Years | 95.13 | 148.3699 | 71.875 | 105.18 | 762,287 | 46.52 | 48.90% |
| 5 Years | 77.55 | 148.3699 | 71.875 | 103.87 | 795,286 | 64.10 | 82.66% |
Neurocrine Biosciences Description
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
